Target Name: RNF11
NCBI ID: G26994
Review Report on RNF11 Target / Biomarker Content of Review Report on RNF11 Target / Biomarker
RNF11
Other Name(s): SID1669 | CGI-123 | Ring finger protein 11 | Zinc finger protein 364 | RING-type E3 ubiquitin transferase RNF115 | RING finger protein 115 | RNF-11 | RING finger protein 11 | RNF11_HUMAN | Rabring 7 | ring finger protein 11

SID Fingerprint: A Potential Drug Target and Biomarker

RNA-Nucleic Acid (RNA) fingerprints are a type of genetic signature that are present in the DNA of all living organisms. These fingerprints are unique and can be used to identify individuals, study gene expression, and identify potential drug targets. One of the most well-known RNA-Nucleic Acid fingerprints is the Simple-Order-Difference (SID) fingerprint. The SID fingerprint is a type ofRNA-Nucleic Acid fingerprint that is present in all living organisms and is composed of a series of connected pseudoknots.

The SID fingerprint is made up of a series of overlapping pseudoknots that are composed of a specific sequence of nucleotides. These nucleotides are usually adenine (A), guanine (G), and cytosine (C), but they can also include other nucleotides such as uracil (U), thymine (T), and hypoxic (H). The length of the SID fingerprint can vary, but it is typically around 30-50 nucleotides in length.

The SID fingerprint is of interest as a potential drug target because it is highly conserved across different organisms and is present in all living organisms. This means that any drug that is effective in treating one organism is likely to be effective in treating others as well. Additionally, because the SID fingerprint is relatively simple, it is easy to identify and can be used as a biomarker for certain diseases.

One of the most promising uses for the SID fingerprint is as a drug target for cancer. Many cancer treatments are designed to target specific molecules within the cell, and the SID fingerprint is a potential target for many different types of cancer. For example, the SID fingerprint is often used to identify proteins that are involved in cell signaling pathways, and many cancer therapies work by targeting these proteins. Additionally, the SID fingerprint is also often used to identify proteins that are involved in cell division and growth, which is an important factor in the development and progression of many types of cancer.

Another potential use for the SID fingerprint is as a biomarker for certain diseases. Many diseases, such as diabetes and heart disease, are characterized by the buildup of plaque in the arteries. The SID fingerprint has been shown to be present in the plaques of individuals with diabetes and heart disease. Additionally, the SID fingerprint has also been shown to be present in the nuclei of cancer cells, which suggests that it may be a useful biomarker for certain types of cancer.

The SID fingerprint is also of interest as a potential drug target because of its unique composition. The SID fingerprint is composed of a specific sequence of nucleotides, which makes it relatively easy to identify and target. Additionally, because the SID fingerprint is relatively simple, it is easy to generate new SIDs with different lengths and sequences, which can be used to identify new potential drug targets.

In conclusion, the SID fingerprint is a type of RNA-Nucleic Acid fingerprint that is present in all living organisms. It is composed of a series of overlapping pseudoknots and is of interest as a potential drug target and biomarker for cancer and other diseases. Further research is needed to fully understand the potential of the SID fingerprint as a drug target and biomarker.

Protein Name: Ring Finger Protein 11

Functions: Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. Promotes the association of TNFAIP3 to RIPK1 after TNF stimulation. TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Recruits STAMBP to the E3 ubiquitin-ligase SMURF2 for ubiquitination, leading to its degradation by the 26S proteasome

The "RNF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF111 | RNF112 | RNF113A | RNF113B | RNF114 | RNF115 | RNF121 | RNF122 | RNF123 | RNF125 | RNF126 | RNF126P1 | RNF128 | RNF13 | RNF130 | RNF133 | RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP